Sanara MedTech (SMTI) vs Stereotaxis (STXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Sanara MedTech (SMTI) has outperformed Stereotaxis (STXS) over the past year, gaining 10.9% versus a loss of 67.1%. Over five years, SMTI leads with a +6.3% price change compared with -81.3% for STXS. Sanara MedTech is the larger company by market cap ($322.2 million vs $111.2 million), about 2.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SMTI | STXS |
|---|---|---|
| Share price | $35.07 | $1.11 |
| Market cap | $322.22M | $111.22M |
| 1-day change | +0.06% | 0.00% |
| YTD return | +50.19% | -51.74% |
| 1-year return | +10.95% | -67.06% |
| 5-year return | +6.34% | -81.28% |
| Forward P/E | 64.94 | — |
| EPS (TTM) | $-0.04 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.34 | $3.20 |
| 52-week low | $16.05 | $1.09 |
| Distance from 52-week high | -0.76% | -65.31% |
| Analyst consensus | none | none |
| Avg. price target upside | -0.20% | +170.27% |
| Average volume | 280.40K | 812.23K |
| Shares outstanding | 9.19M | 100.20M |
| Employees | 108 | 131 |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Sanara MedTech is about 2.9 times larger than Stereotaxis by market value ($322.22M vs $111.22M).
- SMTI has outperformed STXS by 78.0 percentage points over the past year.
About Sanara MedTech
SMTI stock →Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns.
Health Care · Industrial Specialties · 108 employees
About Stereotaxis
STXS stock →Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 131 employees
SMTI vs STXS FAQ
Which is bigger, Sanara MedTech or Stereotaxis?
Sanara MedTech (SMTI) is larger, with a market capitalization of $322.22M compared with $111.22M for Stereotaxis (STXS).
Which stock has performed better over the past year, SMTI or STXS?
SMTI returned +10.95% over the past 12 months, compared with -67.06% for STXS (price return, excluding dividends). Past performance does not predict future results.
Are Sanara MedTech and Stereotaxis in the same industry?
Both are in the Health Care sector, but in different industries: Industrial Specialties for Sanara MedTech and Biotechnology: Electromedical & Electrotherapeutic Apparatus for Stereotaxis.